The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Cited by
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W.-C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304594 · Cited by 672
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Self-citationHerbst, R. S., Wu, Y.-L., John, T., Grohe, C., Majem, M., Wang, J., Kato, T., Goldman, J. W., Laktionov, K., Kim, S.-W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02186 · Cited by 408
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Self-citationXiong, A., Ren, S., Liu, H., Miao, L., Wang, L., Chen, J., Li, W., Li, R., Wang, X., Lu, Z., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.06.013 · Cited by 20
Self-citation
Metadata
- Authors
- He, J., Su, C., Liang, W., Xu, S., Wu, L., Fu, X., Zhang, X., Ge, D., Chen, Q., Mao, W., Xu, L., Chen, C., Hu, B., Shao, G., Hu, J., Zhao, J., Liu, X., Liu, Z., Wang, Z., Xiao, Z., Gong, T., Lin, W., Li, X., Ye, F., Liu, Y., Ma, H., Huang, Y., Zhou, J., Wang, Z., Fu, J., Ding, L., Mao, L., & Zhou, C.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 9
- Issue
- 9
- Pages
- 1021-1029
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W3186743916
- Cited by
- 185
- References
- 1
- FWCI
- 19.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(21)00134-x
- The paper
- He, J., Su, C., Liang, W., Xu, S., Wu, L., Fu, X., Zhang, X., Ge, D., Chen, Q., Mao, W., Xu, L., Chen, C., Hu, B., Shao, G., Hu, J., Zhao, J., Liu, X., Liu, Z., Wang, Z., . . . Zhou, C. (2021). Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(21)00134-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.